Clinical trials: Chicken Pox
Herpes Zoster
Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to…
- Trial name
- NCT05636436
- Testing
- Low Dose Recombinant Herpes Zoster Vaccine (CHO cells), High Dose Recombinant Herpes Zoster Vaccine (CHO cells), Low dose adjuvant
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Measles, Mumps
Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
This study will assess the safety and immunogenicity of ProQuad when administered concomitantly and nonconcomitantly with Tripedia and Comvax.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00984295
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Tripedia, Comparator: Comvax
- Volunteers
- 1,913 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Virus Diseases, Herpes Zoster
Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles
Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders.
- Trial name
- 168 (NCT00921934)
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Measles, Varicella
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
This study is undertaken to generate clinical data on GSK Biologicals' combined measles-mumps-rubella-varicella vaccine manufactured with measles and rubella obtained from newly established working seed viruses which are one…
- Conditions
- Measles, Varicella, Mumps, Rubella
- Trial name
- NCT00892775
- Testing
- Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), GSK Biologicals' 208136, new formulation
- Where
- 6 sites in Singapore, Taiwan
- Volunteers
- 501 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)
The purpose of this study is to determine whether the refrigerator-stable formulation of an investigational vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile to that of…
- Trial name
- NCT00130793
- Testing
- Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation, Comparator: zoster vaccine live (Oka/Merck) frozen formulation
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postherpetic Neuralgia
Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia
This is a Phase 2 randomized, double-blind, placebo-controlled, multiple-dose, multicenter, parallel-group study to evaluate the analgesic activity of ATx08-001, a novel selective peroxisome proliferator-activated receptor…
- Trial name
- NCT01318226
- Testing
- ATx08-001
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- Aestus Therapeutics
Herpes Zoster, Neuralgia
Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain
This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products.
- Conditions
- Herpes Zoster, Neuralgia, Pain, HIV Infections
- Trial name
- NCT00082316
- Testing
- Capsaicin Dermal Patch
- Where
- 17 sites in United States
- Sponsor
- NeurogesX
Herpes Zoster
Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects
Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles).
- Trial name
- NCT00434577
- Testing
- Herpes Zoster vaccine GSK1437173A Low Dose, Herpes Zoster vaccine GSK1437173A Medium Dose, Herpes Zoster vaccine GSK1437173A High Dose
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
Study of Two Formulations of GSK Biologicals' Varicella Vaccine
The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety.
- Trial name
- NCT00568334
- Testing
- Varilrix (inactivated varicella vaccine)
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Disorders
Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01. The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered…
- Trial name
- NCT03894969
- Testing
- GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E, Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
- Where
- 14 sites in Estonia, Finland and 3 more
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
Re-examination Study For Varivax (V210-059 AM2)
This survey is conducted for preparing application materials for re-examination under the Korean Pharmaceutical Affairs Laws and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of VARIVAX through…
- Trial name
- NCT01062061
- Testing
- VARIVAX™
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above
The study aims to estimate the incidence of herpes zoster (HZ), proportion of postherpetic neuralgia (PHN) and the economic burden and impact on quality of life, in Japanese adults greater than or equal to sixty years of age.
- Trial name
- NCT01873365
- Testing
- Data collection
- Where
- 14 sites in Japan
- Volunteers
- 448 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults
This is a Phase I，randomized, double-blind, placebo controlled,dose escalated,single administrated clinical trial in Chinese healthy adult's volunteers.
- Trial name
- NCT05639803
- Testing
- PEGIFNα1b
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Post Herpetic Neuralgia
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia
The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.
- Trial name
- NCT01748877
- Testing
- NXN-462
- Where
- 25 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- NeurAxon Inc.
Herpes Zoster
A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)
The purpose of this study was to assess the safety and tolerability of gamma-irradiated varicella-zoster virus (VZV) vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) and to determine if they were immunogenic…
- Trial name
- NCT00696709
- Testing
- Comparator: V212
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Herpes Zoster (HZ)
Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
- Trial name
- NCT06874842
- Testing
- Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Healthy
Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)
This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.
- Trial name
- NCT00092417
- Testing
- Comparator: Varicella Zoster Virus Vaccine
- Volunteers
- 695 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC